CN103877533B - Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof - Google Patents
Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof Download PDFInfo
- Publication number
- CN103877533B CN103877533B CN201310732027.5A CN201310732027A CN103877533B CN 103877533 B CN103877533 B CN 103877533B CN 201310732027 A CN201310732027 A CN 201310732027A CN 103877533 B CN103877533 B CN 103877533B
- Authority
- CN
- China
- Prior art keywords
- metformin
- pharmaceutical composition
- treatment
- diabetes
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960003105 metformin Drugs 0.000 title claims abstract description 61
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 39
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims description 16
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002496 gastric effect Effects 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000013543 active substance Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 108010075254 C-Peptide Proteins 0.000 description 7
- 229920000858 Cyclodextrin Polymers 0.000 description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 7
- 238000005507 spraying Methods 0.000 description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 6
- 239000000811 xylitol Substances 0.000 description 6
- 235000010447 xylitol Nutrition 0.000 description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 6
- 229960002675 xylitol Drugs 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- -1 tie up main plain E Natural products 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to medical art, be specifically related to pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof.The pharmaceutical composition of the treatment diabetes containing metformin of the present invention, is made up of the crude drug of following weight: metformin 250-750 part, Rhizoma Pinelliae 1500-2500 part, Rhizoma Zingiberis Recens 2500-3500 part, Fructus Aurantii 2500-3500 part, Pericarpium Citri Reticulatae 1500-2500 part, Rhizoma Coptidis 1500-2500 part.Chinese medicine combines with metformin by the present invention, can avoid the common gastrointestinal side effect of metformin, and improves the therapeutic effect to diabetes.
Description
Technical field
The invention belongs to medical art, be specifically related to pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof.
Background technology
Diabetes are second killers in modern diseases, and it is only second to cancer to the harm of human body.In fact, diabetes itself are not fearful, and the complication of diabetes that fearful is, the harm that diabetes are brought, nearly all from its complication.In China's diabetics, complicated hypertension person reaches 1,200 ten thousand, apoplexy person 5,000,000, coronary disease patient 6,000,000, and the person of losing the sight of both eyes 450,000, uremia person 500,000.
Diabetes are a kind of complex diseases because of syndrome, be because the hormone of insulin deficit in body or antagonism insulin increases, or insulin can not be brought into normal play physiological action and a kind of syndrome of glucose, protein and lipid metabolic disorder of causing in target cell.To it is characterized by blood circulation that concentration of glucose is abnormal to be raised and glucose in urine, blood glucose occur typical " three-many-one-little " symptom time too high, namely to eat more, polyuria, polyphagia and lose weight, and with fatigue and weak.Can be there is ketoacidosis, hypertonicity diabetic coma in severe patient, and easily merge multi-infection.Along with the prolongation of the course of disease, its metabolism disorder can cause the chronic disease of the histoorgans such as eye, kidney, nerve, blood vessel and heart.If can not get timely, appropriate treatment, then there is heart change, cerebrovascular disease, renal failure, lose the sight of both eyes, the situation such as lower limbs necrosis, become disable, lethal main cause.
Metformin is the biguanides of clinical conventional treatment diabetes, is applicable to alone diet and exercise therapy and can not obtains the good type 2 diabetes mellitus patient controlled.This product can medication separately, also can share with sulphanylureas or insulin.The diabetes effect being used for the treatment of obese type is fine, therefore clinical practice is extensive, the common untoward reaction of metformin is gastrointestinal upset, as nausea,vomiting,diarrhea, stomachache, constipation, abdominal distention, dyspepsia, heartburn, this untoward reaction is up to 30%, and this untoward reaction limits the use of metformin.
Summary of the invention
In order to solve the technical problem of metformin gastrointestinal side effect large restriction end user group, the invention provides the compositions of a kind of metformin and Chinese medicine, by the compatibility with Chinese medicine, alleviating the untoward reaction of metformin, thus realize the object of attenuation synergistic.
The present invention is realized by following technical scheme:
A pharmaceutical composition for treatment diabetes containing metformin, is made up of the crude drug of following weight proportion: metformin 250-750 part, Rhizoma Pinelliae 1500-2500 part, Rhizoma Zingiberis Recens 2500-3500 part, Fructus Aurantii 2500-3500 part, Pericarpium Citri Reticulatae 1500-2500 part, Rhizoma Coptidis 1500-2500 part.
The pharmaceutical composition of the above-mentioned treatment diabetes containing metformin, its weight is preferably: metformin 400-600 part, Rhizoma Pinelliae 1800-2200 part, Rhizoma Zingiberis Recens 2800-3200 part, Fructus Aurantii 2800-3200 part, Pericarpium Citri Reticulatae 450-2200 part, Rhizoma Coptidis 1800-2200 part.
The pharmaceutical composition of the above-mentioned treatment diabetes containing metformin, its weight the best is:: metformin 500 parts, the Rhizoma Pinelliae 2000 parts, 3000 parts, Rhizoma Zingiberis Recens, Fructus Aurantii 3000 parts, Pericarpium Citri Reticulatae 2000 parts, Rhizoma Coptidis 2000 parts.
In above composition of the present invention, the weight of each taste Chinese medicine calculates, if in grams, as made preparation, then because varying in size of preparation can be made into 100-1000 agent with crude drug.Described 100-1000 agent refers to the dosage form of unit dose, as tablet 100-1000 sheet, and capsule 100-1000 grain, granule l00-1000g, oral liquid l00-l000ml, unguentum l00-l000g, pill 100-1000 ball etc.
More than composition is by weight as proportioning, can increase according to corresponding proportion when producing or reduce, as large-scale production can in units of kg, or with t (ton) for unit; Preparation also can in units of g on a small scale.Weight can increase or reduce, but the constant rate of raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion is through that science screening obtains, and for especial patient, as serious symptom or mild, fat or modest patient, can the proportioning of amount of corresponding adjustment composition, and increase or reduce being no more than 100%, drug effect is substantially constant.
Chinese medicine composition of the present invention, can add the acceptable adjuvant of some medicines separately or as required, galenic pharmacy routine techniques can be adopted to prepare this pharmaceutical preparation, as mixed by acceptable to pharmaceutically active substance and medicine adjuvant.Can make any pharmaceutically useful peroral dosage form when making pharmaceutical preparation, these dosage forms are selected from: granule, tablet, capsule, oral liquid, suck agent, pill, powder, preferably granule.
The preparation method of the pharmaceutical composition of the above-mentioned treatment diabetes containing metformin, comprises following steps:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 6 ~ 8 times of water gagings the 1st time, decoct 1 ~ 2 hour, second time adds 4 ~ 6 times of water gagings, decocts 0.5 ~ 1.5 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 55 ~ 65 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.04 ~-0.08Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, filters, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance separately or mix with medicine acceptable adjuvant, obtained according to galenic pharmacy conventional method.
In the preparation method of the pharmaceutical composition of the above-mentioned treatment diabetes containing metformin, add 7 times of water gagings the 1st time, decoct 1.5 hours in institute portion step a, second time adds 5 times of water gagings, decocts 1 hour; In described step b, thickening temperature is 60 DEG C, concentrated pressure is-0.06Mpa.
Preferably, state the preparation method of the pharmaceutical composition of the treatment diabetes containing metformin, detailed step is as follows:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 7 times of water gagings the 1st time, decoct 1.5 hours, second time adds 5 times of water gagings, decocts 1 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 60 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.06Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance separately or mix with medicine acceptable adjuvant, obtained according to galenic pharmacy conventional method.
The acceptable adjuvant of described medicine is selected from: starch, magnesium stearate, mannitol, sorbitol, sorbic acid or potassium salt, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin A, vitamin C, tie up main plain E, vitamin D, azone, EDETATE SODIUM, Ethylenediaminetetraacetic Acid Calcium Salt, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, dextran, glycine, lactose, mannitol, silicon derivative, cellulose and its derivates, alginate, gelatin, polyvinylpyrrolidone, glycerol, propylene glycol, ethanol, polysorbate60 ~ 80, department class ~ 80, Cera Flava, lanoline, liquid paraffin, hexadecanol, gallate ester, fine jade, triethanolamine, basic amino acid, carbamide, allantoin, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, β ~ cyclodextrin, phospholipid material, Kaolin, Pulvis Talci, calcium stearate etc.
The pharmaceutical composition that the present invention treats diabetes is applicable to alone diet and exercise therapy can not obtain good control and the Body Mass Index BMI type 2 diabetes mellitus patient that is greater than 35.This product can medication separately, also can share with sulphanylureas or insulin, be particularly suitable for insulin resistant, and insulin or C peptide secretion test, higher than the patient of normal value, also can be share with antioxidant.
The present invention treats the pharmaceutical composition usage and dosage of diabetes:
Oral: cumulative dosage from low dose.Usual initial dose be one time 1 bag, 2 times on the one; Take with meal.
The pharmaceutical composition that the present invention treats diabetes to be forbidden in type 2 diabetes mellitus with ketoacidosis, hepatic and kidney function obstacle, heart failure, acute myocardial infarction, severe infections and wound, capital operation, clinically has hypotension and anaerobic condition, is previously had lactic acidosis history person, and forbids this product allergy sufferers.
Beneficial effect of the present invention is: Chinese medicine combines with metformin by the present invention, to avoid the common gastrointestinal side effect of metformin, and improves the therapeutic effect to diabetes.Clinical test results shows: oral the present invention containing the patient of combination with metformin thing, preliminary judgement in the blood glucose fluctuation time, improve carbohydrate tolerance, improve in insulin and the release of C peptide and be better than simple application base metformin person.In addition, the metformin pharmaceutical composition that contains of the present invention is improving in metformin medicine gastrointestinal side effect than simple application metformin person's Be very effective (P < 0.05).Illustrate and of the present inventionly truly have curative effect containing metformin pharmaceutical composition improving in insulin resistant, protection islet cell function, and there is the little advantage of side effect.
Accompanying drawing explanation
Accompanying drawing 1 is C peptide release profiles after two groups of patient treatments in clinical trial data of the present invention.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described, so that those skilled in the art more understands the present invention, but does not therefore limit the present invention.
Embodiment 1
Treat a pharmaceutical composition for diabetes, be made up of the crude drug of following weight:
Metformin 500g, Rhizoma Pinelliae 2000g, Rhizoma Zingiberis Recens 3000g, Fructus Aurantii 3000g, Pericarpium Citri Reticulatae 2000g, Rhizoma Coptidis 2000g.
The preparation method of the pharmaceutical composition of these treatment diabetes:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 7 water gagings the 1st time, decoct 1.5 hours, second time adds 5 times of water gagings, decocts 1 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 60 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.06Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance adds xylitol, mannitol and β ~ cyclodextrin, and binding agent makes granule in right amount.
Prepare 1000 bags altogether, every bag heavy 5g.
Embodiment 2
Treat a pharmaceutical composition for diabetes, be made up of the crude drug of following weight:
Metformin 400g, Rhizoma Pinelliae 2200g, Rhizoma Zingiberis Recens 2800g, Fructus Aurantii 3200g, Pericarpium Citri Reticulatae 1800g, Rhizoma Coptidis 1800g.
The preparation method of the pharmaceutical composition of these treatment diabetes:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 8 water gagings the 1st time, decoct 2 hours, second time adds 6 times of water gagings, decocts 1.5 hours, merges decoction liquor, for subsequent use;
B. by decoction liquor 55 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.08Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance adds xylitol, mannitol and β ~ cyclodextrin, binding agent makes granule in right amount.
Prepare 1000 bags altogether, every bag heavy 5g.
Embodiment 3
Treat a pharmaceutical composition for diabetes, be made up of the crude drug of following weight:
Metformin 600g, Rhizoma Pinelliae 1800g, Rhizoma Zingiberis Recens 3200g, Fructus Aurantii 2800g, Pericarpium Citri Reticulatae 2200g, Rhizoma Coptidis 2200g.
The preparation method of the pharmaceutical composition of these treatment diabetes:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 6 water gagings the 1st time, decoct 1 hour, second time adds 4 times of water gagings, decocts 0.5 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 65 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.04Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance adds xylitol, mannitol and β ~ cyclodextrin, and binding agent makes granule in right amount.
Prepare 1000 bags altogether, every bag heavy 5g.
Embodiment 4
Treat a pharmaceutical composition for diabetes, be made up of the crude drug of following weight:
Metformin 250g, Rhizoma Pinelliae 2500g, Rhizoma Zingiberis Recens 2500g, Fructus Aurantii 3500g, Pericarpium Citri Reticulatae 1500g, Rhizoma Coptidis 2500g.
The preparation method of the pharmaceutical composition of these treatment diabetes:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 7 water gagings the 1st time, decoct 1.5 hours, second time adds 5 times of water gagings, decocts 1 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 60 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.06Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance adds xylitol, mannitol and β ~ cyclodextrin, and binding agent makes granule in right amount.
Prepare 1000 bags altogether, every bag heavy 5g.
Embodiment 5
Treat a pharmaceutical composition for diabetes, be made up of the crude drug of following weight:
Metformin 750g, Rhizoma Pinelliae 1500g, Rhizoma Zingiberis Recens 3500g, Fructus Aurantii 2500g, Pericarpium Citri Reticulatae 2500g, Rhizoma Coptidis 1500g.
The preparation method of the pharmaceutical composition of these treatment diabetes:
A. the Rhizoma Pinelliae, Rhizoma Zingiberis Recens, Fructus Aurantii, Pericarpium Citri Reticulatae, Rhizoma Coptidis are decocted with water 2 times, add 7 water gagings the 1st time, decoct 1.5 hours, second time adds 5 times of water gagings, decocts 1 hour, merges decoction liquor, for subsequent use;
B. by decoction liquor 60 DEG C, be condensed into the clear paste that relative density is 1.08 ~ 1.12 under-0.06Mpa condition, adding ethanol to alcohol content is 75%, places 12 hours, and filter, filtrate is concentrated into the clear paste that relative density is 1.15 ~ 1.20, and spraying dry obtains dry medicated powder;
C. metformin and dry medicated powder are mixed, granulate, obtain the active substance of Chinese medicine composition of the present invention;
D. this active substance adds xylitol, mannitol and β ~ cyclodextrin, and binding agent makes granule in right amount.
Prepare 1000 bags altogether, every bag heavy 5g.
Carried out clinical trial to the pharmaceutical composition containing metformin prepared by embodiment 1, result is as follows:
1. data and method
Object of study
This research of 60 routine type 2 diabetes mellitus patient selection, all meets WHO diagnostic criteria in 1999, and meets following condition: 1. make a definite diagnosis for the first time or make a definite diagnosis and be no more than half a year and do not treat and fasting glucose >=11.1mmol/L; 2. without serious acute and chronic complication.
Therapeutic Method
Qualified 60 routine patients are divided into two groups at random.1. matched group: use in conjunction metformin on the basis of patient being carried out to the education of diabetes health knowledge and Diet Therapy, each 0.5g of metformin, every day 2 times.2. treatment group: use in conjunction contains the pharmaceutical composition of metformin on the basis of patient being carried out to the education of diabetes health knowledge and Diet Therapy, each 1 bag, every day 2 times.Two groups of patients no significant difference in sex, age, Body Mass Index, glycolated hemoglobin, the distribution of fasting glucose, roughly disease time.
Observation index
1. safety indexes: as routine blood test, stool routine examination, liver function, kidney function test, electrocardiogram etc.; 2. health giving quality index: Body Mass Index, blood glucose fluctuation time before and after treatment; 3. lab testing: the experiment of the glycolated hemoglobin after treatment, carbohydrate tolerance, insulin and C peptide release test.3. gastrointestinal side effect index: as Nausea and vomiting, abdominal distention, stomachache etc.
Statistical method
SPSS17.0 is adopted to carry out the statistical analysis of data.Measurement data adopts t inspection (representing by mean ± standard deviation); Group data adopts χ
2inspection, using P≤0.05 as there being statistical significance, using P≤0.01 as there being height statistical significance.
2. result
Clinical efficacy result
Difference (P > 0.05) that before and after Body Mass Index treatment, there are no significant.Blood glucose fluctuation chronotherapy is obviously less than matched group (P < 0.05), in table 1.
Table 1 liang group patient blood glucose reaching standard time
relatively (X ± s)
Laboratory examination results after treatment
Glycolated hemoglobin treatment group lower than matched group, result there was no significant difference (P > 0.05).Carbohydrate tolerance test: 3h two groups of there was no significant differences (P > 0.05) after the meal, remaining chronotherapy group reduction (P < 0.05) more obvious than matched group.C peptide release test: treatment group comparatively matched group discharges showed increased (P < 0.05), 2h, 3h there was no significant difference (P > 0.05) after the meal on an empty stomach and after the meal 1h.Insulin release test: 1h treatment group is matched group insulin releasing showed increased (P < 0.01) comparatively; The remaining time two groups of there was no significant differences (P > 0.05).Analyze insulin releasing curve, treatment group secretion peak is more obvious and obvious in the falling of 2h amount of insulin secretion, shows that islet function recovers to be better than matched group.In Table 2-5 and accompanying drawing 1.
HbA1c (%) results contrast (X ± s) before and after table 2 liang group patient treatment
Carbohydrate tolerance test before and after table 3 liang group patient treatment
result (X ± s)
C peptide release test before and after table 4 liang group patient treatment
result (X ± s)
Insulin release test (Uu/ before and after table 5 liang group patient treatment
ml) result (X ± s)
Safety observations result
In this test, whole experimenter carries out safety indexes detection respectively before and after treatment, and result does not find obvious abnormal change, the pharmaceutical composition use safety containing metformin of the present invention is described, without obvious adverse reaction.
Gastrointestinal side effect result
Gastrointestinal side effect matched group is starkly lower than treatment group (P < 0.05).In table 6.
A table 6 liang group adverse reactions of patients number compares
3 conclusions
Oral the present invention containing the patient of combination with metformin thing, preliminary judgement in the blood glucose fluctuation time, improve carbohydrate tolerance, improve in insulin and the release of C peptide and be better than simple application base metformin person.In addition, the metformin pharmaceutical composition that contains of the present invention is improving in metformin medicine gastrointestinal side effect than simple application metformin person's Be very effective (P < 0.05).Illustrate and of the present inventionly truly have curative effect containing metformin pharmaceutical composition improving in insulin resistant, protection islet cell function, and there is the little advantage of side effect.
Claims (4)
1. a pharmaceutical composition for the treatment diabetes containing metformin, be made up of the crude drug of following weight:
Metformin 250-750 part, Rhizoma Pinelliae 1500-2500 part, Rhizoma Zingiberis Recens 2500-3500 part, Fructus Aurantii 2500-3500 part, Pericarpium Citri Reticulatae 1500-2500 part, Rhizoma Coptidis 1500-2500 part.
2. the pharmaceutical composition of the treatment diabetes containing metformin as claimed in claim 1, it is characterized in that, be made up of the crude drug of following weight: metformin 400-600 part, Rhizoma Pinelliae 1800-2200 part, Rhizoma Zingiberis Recens 2800-3200 part, Fructus Aurantii 2800-3200 part, Pericarpium Citri Reticulatae 1800-2200 part, Rhizoma Coptidis 1800-2200 part.
3. the pharmaceutical composition of the treatment diabetes containing metformin as claimed in claim 2, it is characterized in that, be made up of the crude drug of following weight: metformin 500 parts, the Rhizoma Pinelliae 2000 parts, 3000 parts, Rhizoma Zingiberis Recens, Fructus Aurantii 3000 parts, Pericarpium Citri Reticulatae 2000 parts, Rhizoma Coptidis 2000 parts.
4. the pharmaceutical composition of the treatment diabetes containing metformin as described in claim 1 or 2 or 3, it is characterized in that, its dosage form is granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310732027.5A CN103877533B (en) | 2013-12-25 | 2013-12-25 | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310732027.5A CN103877533B (en) | 2013-12-25 | 2013-12-25 | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103877533A CN103877533A (en) | 2014-06-25 |
| CN103877533B true CN103877533B (en) | 2016-04-20 |
Family
ID=50946869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310732027.5A Active CN103877533B (en) | 2013-12-25 | 2013-12-25 | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103877533B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497559A (en) * | 2015-12-17 | 2016-04-20 | 刘爱华 | Pharmaceutical composition with blood glucose lowering function |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011561A (en) * | 2006-11-01 | 2007-08-08 | 黄达驹 | Huanglian Wendan Decoction modern traditional Chinese medicine oral preparation and production method thereof |
| CN101810849A (en) * | 2010-04-20 | 2010-08-25 | 南京凯瑞尔纳米生物技术有限公司 | Medicament for curing diabetes |
| CN102908599A (en) * | 2012-06-19 | 2013-02-06 | 谢文龙 | Medicine capable of reducing blood sugar, blood fat and blood pressure |
-
2013
- 2013-12-25 CN CN201310732027.5A patent/CN103877533B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011561A (en) * | 2006-11-01 | 2007-08-08 | 黄达驹 | Huanglian Wendan Decoction modern traditional Chinese medicine oral preparation and production method thereof |
| CN101810849A (en) * | 2010-04-20 | 2010-08-25 | 南京凯瑞尔纳米生物技术有限公司 | Medicament for curing diabetes |
| CN102908599A (en) * | 2012-06-19 | 2013-02-06 | 谢文龙 | Medicine capable of reducing blood sugar, blood fat and blood pressure |
Non-Patent Citations (1)
| Title |
|---|
| 黄连温胆汤治疗糖尿病并发症4则;王永山;《新中医》;20090205(第02期);96-97 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103877533A (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101890040B (en) | Composition with anti-fatigue effect and application thereof | |
| CN103784727A (en) | Traditional Chinese medicinal composition, compound preparation and application thereof | |
| JP2011522844A (en) | Composition for reducing blood glucose level and use thereof | |
| CN101612159B (en) | Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament | |
| CN103877533B (en) | Pharmaceutical composition of a kind for the treatment of diabetes containing metformin and preparation method thereof | |
| CN105616581A (en) | Glipizide-containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| US20220047658A1 (en) | Tcm addition and subtraction prescription used prevention/treatment of metabolic syndrome and complications | |
| CN102125671B (en) | Traditional Chinese medicinal composition for treating gynaecopathia caused by deficiency of the kidney and cold and preparation method thereof | |
| CN102579947B (en) | Chinese medicinal composition and preparation method thereof | |
| CN106177712A (en) | A kind of magnificent Bulbus Allii bean treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN101732657A (en) | Medicine composition | |
| CN105796952A (en) | Gliquidone-containing medicine combination for treating diabetes and preparation method thereof | |
| CN100571722C (en) | Treatment is suffered from a deficiency of the kidney and the pharmaceutical composition of climacteric syndrome and preparation method thereof | |
| CN103230552A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN102772540B (en) | A kind of medicine for the treatment of metabolism syndrome | |
| CN101439109A (en) | Chinese herbal medicinal composition for treating enterogastric disease and preparation method and use | |
| CN101036714B (en) | Medicinal composition for treating and/or preventing diabetes | |
| CN107019771A (en) | A kind of antineoplastic Chinese medicine composition | |
| CN101773620A (en) | Heat-clearing stranguria-treating drug | |
| CN101347483A (en) | Chinese herbal medicinal composition for treating enterogastric disease and preparation method and use | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN105709100A (en) | Medicine composition for treating diabetes containing rosiglitazone and preparation method of medicine composition | |
| CN105687599A (en) | Glibenclamide containing pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN105617119A (en) | Gliclazide-containing pharmaceutical composition for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Pang Yuelin Inventor after: Li Peigang Inventor after: Zhang Fan Inventor after: Wang Desheng Inventor after: Wang Qingyu Inventor after: Liu Hua Inventor before: Meng Xiaofei |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160322 Address after: 550018 Guizhou Province, Guiyang city Wudang District High Road No. 25 Applicant after: GUIZHOU TIANAN PHARMACEUTICAL CO.,LTD. Address before: 250023 dormitory 7-4-201, Ji'nan boiler factory, 2 Huanggang Road, Tianqiao District, Shandong, Ji'nan Applicant before: Meng Xiaofei |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 550018 Guizhou Province, Guiyang city Wudang District High Road No. 25 Patentee after: Shuanghe Tian'an Pharmaceutical (Guizhou) Co.,Ltd. Country or region after: China Address before: 550018 Guizhou Province, Guiyang city Wudang District High Road No. 25 Patentee before: GUIZHOU TIANAN PHARMACEUTICAL CO.,LTD. Country or region before: China |
|
| CP03 | Change of name, title or address |